222 related articles for article (PubMed ID: 19162045)
41. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
42. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Tian Y; Zhao L; Wang Y; Zhang H; Xu D; Zhao X; Li Y; Li J
Asian J Androl; 2016; 18(4):607-12. PubMed ID: 26698234
[TBL] [Abstract][Full Text] [Related]
43. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
[TBL] [Abstract][Full Text] [Related]
44. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
45. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
46. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
[TBL] [Abstract][Full Text] [Related]
47. Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis.
Nakamura Y; Hornsby PJ; Casson P; Morimoto R; Satoh F; Xing Y; Kennedy MR; Sasano H; Rainey WE
J Clin Endocrinol Metab; 2009 Jun; 94(6):2192-8. PubMed ID: 19336506
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
[TBL] [Abstract][Full Text] [Related]
49. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
50. AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.
Zhao J; Xiang Y; Xiao C; Guo P; Wang D; Liu Y; Shen Y
Int J Med Sci; 2014; 11(11):1089-97. PubMed ID: 25170291
[TBL] [Abstract][Full Text] [Related]
51. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
[TBL] [Abstract][Full Text] [Related]
52. Disialoganglioside GD3 synthase expression recruits membrane transglutaminase 2 during erythroid differentiation of the human chronic myelogenous leukemia K562 cells.
Kang SK; Kim YS; Kong YJ; Song KH; Chang YC; Park YG; Ko JH; Lee YC; Kim CH
Proteomics; 2008 Aug; 8(16):3317-28. PubMed ID: 18690648
[TBL] [Abstract][Full Text] [Related]
53. Differential expression of the enzymatic system controlling synthesis, metabolism, and transport of PGF2 alpha in human fetal membranes.
Breuiller-Fouché M; Leroy MJ; Dubois O; Reinaud P; Chissey A; Qi H; Germain G; Fortier MA; Charpigny G
Biol Reprod; 2010 Jul; 83(1):155-62. PubMed ID: 20357271
[TBL] [Abstract][Full Text] [Related]
54. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice.
Verrax J; Stockis J; Tison A; Taper HS; Calderon PB
Biochem Pharmacol; 2006 Sep; 72(6):671-80. PubMed ID: 16828058
[TBL] [Abstract][Full Text] [Related]
55. Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues.
Sharma KK; Lindqvist A; Zhou XJ; Auchus RJ; Penning TM; Andersson S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):79-86. PubMed ID: 16337083
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
57. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
58. Methylation status of RASSF1A in patients with chronic myeloid leukemia.
Avramouli A; Tsochas S; Mandala E; Katodritou E; Ioannou M; Ritis K; Speletas M
Leuk Res; 2009 Aug; 33(8):1130-2. PubMed ID: 19193434
[TBL] [Abstract][Full Text] [Related]
59. [Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia].
Meng YS; Wei R; Ai GW; Meng XQ; Zhang YX
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):890-3. PubMed ID: 19671288
[TBL] [Abstract][Full Text] [Related]
60. Transcript profiling and DNA damage in the European eel (Anguilla anguilla L.) exposed to 7,12-dimethylbenz[a]anthracene.
Nogueira P; Lourenço J; Rodriguez E; Pacheco M; Santos C; Rotchell JM; Mendo S
Aquat Toxicol; 2009 Aug; 94(2):123-30. PubMed ID: 19586669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
